Can regional analgesia reduce the risk of recurrence after breast cancer?: Methodology of a multicenter randomized trial

Sessler, Daniel I., Ben-Eliyahu, Shamgar, Mascha, Edward J., Parat, Marie-Odile and Buggy, Donal J. (2008) Can regional analgesia reduce the risk of recurrence after breast cancer?: Methodology of a multicenter randomized trial. Contemporary Clinical Trials, 29 4: 517-526.


Author Sessler, Daniel I.
Ben-Eliyahu, Shamgar
Mascha, Edward J.
Parat, Marie-Odile
Buggy, Donal J.
Title Can regional analgesia reduce the risk of recurrence after breast cancer?: Methodology of a multicenter randomized trial
Journal name Contemporary Clinical Trials   Check publisher's open access policy
ISSN 1551-7144
Publication date 2008-07
Sub-type Article (original research)
DOI 10.1016/j.cct.2008.01.002
Volume 29
Issue 4
Start page 517
End page 526
Total pages 10
Place of publication New York, USA
Publisher Elseiver
Collection year 2009
Language eng
Subject C1
110301 Anaesthesiology
920102 Cancer and Related Disorders
1103 Clinical Sciences
1112 Oncology and Carcinogenesis
Abstract Surgery is the primary and most effective treatment of breast cancer, but minimal residual disease is probably unavoidable. Whether residual disease results in clinical metastases depends on numerous factors, including anti-tumor cell mediated immunity and angiogenic and growth signals in sites of residual disease. At least three perioperative factors adversely affect these: 1) the neuroendocrine stress response to surgery, 2) volatile anesthetics, and 3) opioids. Animal studies indicate that regional anesthesia and optimum postoperative analgesia independently reduce the metastatic burden in animals inoculated with breast adenocarcinoma cells following surgery. Retrospective studies in humans also suggest that regional analgesia may reduce recurrence risk after cancer surgery. We will test the hypothesis that local or metastatic recurrence after breast cancer surgery is lower in patients randomized to paravertebral or high-thoracic epidural analgesia combined with sedation or light anesthesia than in patients given intraoperative volatile anesthesia and postoperative opioid analgesia. In a Phase III, multi-center trial, Stage 1-3 patients having mastectomies for cancer will be randomly assigned to thoracic epidural or paravertebral anesthesia/analgesia, or to sevoflurane anesthesia and morphine analgesia. The primary outcome will be cancer recurrence. Enrolling 1100 patients over 5 years will provide 85% power for detecting a 30% treatment effect at an alpha of 0.05. We plan four equally spaced interim analyses, each evaluating efficacy and futility. Confirming our hypothesis will indicate that a small modification to anesthetic management, one that can be implemented with little risk or cost, will reduce the risk of cancer recurrence -- a complication that is often ultimately lethal.
Keyword Anesthesia
Breast neoplasm
Regional analgesia
Epidural
Regional anesthesia
Paravertebral
Surgery
Q-Index Code C1
Q-Index Status Confirmed Code

Document type: Journal Article
Sub-type: Article (original research)
Collections: 2009 Higher Education Research Data Collection
Excellence in Research Australia (ERA) - Collection
School of Pharmacy Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 44 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 56 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Access Statistics: 105 Abstract Views  -  Detailed Statistics
Created: Wed, 15 Apr 2009, 11:27:33 EST by Elizabeth Pyke on behalf of Faculty Of Health Sciences